Zealand Pharma sends blood sugar drug to US market

The hypoglycemia treatment Zegalogue is now available on the US market, Zealand Pharma reported on Thursday. Three months ago, the US FDA approved the drug for treating very low blood sugar in patients with diabetes.

Photo: Zealand Pharma / PR

Three months after the US Food and Drug Administration authorized Zealand Pharma's drug for severe hypoglycemia, the Danish biotech firm is sending this treatment to the US market.

A Thursday press release states that the drug will be available as both an auto-injector and a prefilled syringe. Zegalogue is meant to be a rescue therapy for diabetes patients experiencing severe episodes of very low blood sugar.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs